Could traditional Chinese medicine hold an answer to the obesity problem?

January 31, 2013

Obesity might be a very modern problem, but a team of scientists from Taiwan and China is turning to the age-old principles of traditional Chinese medicine (TCM) to help fight it.  Breaking research published in the Journal of Biomolecular Structure and Dynamics indicates a possible new direction for the treatment of metabolic syndrome.

Metabolic syndrome, a collective disorder characterised by obesity and multiple clinical disorders, is on the rise. Obesity itself is an endocrine disease caused by the body's inability to handle excessive energy intake. It can lead to serious like hypertension, osteoarthritis, cardiovascular disease, sleep apnea, stroke and type-2 diabetes.

Peroxisome proliferator-activated receptors (PPARs) are key regulators of lipid and ; they are involved in regulating many physiological functions initiated by nutrients, nutraceuticals and phytochemicals. There are three subtypes of PPARs – PPAR-a, PPAR-g and PPAR-∂ –which all play important roles. Because of these roles, the three are also important for treating metabolic syndrome.

TCM compounds have long been recognised as potential lead candidates in creating anti-viral, anti-tumour and anti-inflammation agents. To see whether they might also be used to design agonists targeting PPAR-a, PPAR-g, and PPAR-∂ in the fight against metabolic disease, the researchers consulted the TCM Database@Taiwan, which lists more than 30,000 small-molecule compounds of TCM origin. The team ran a series of models and simulations to virtually screen the database, establishing structure-based pharmacore models for each PPAR protein in order to identify the key actions during docking; and homology modelling were also performed. The results, published in the Journal of Biomolecular Structure and Dynamics, identify two TCM compounds as potential lead compounds in developing agonists targeting multiple PPARs: (S)-tryptophan-betaxanthin and berberrubine. Further research is needed, but the current study points to an exciting new direction for the treatment of metabolic syndrome.

More information: Chen, K. et al. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine, Journal of Biomolecular Structure and Dynamics, Volume 30, Issue 6, 2012, DOI: 10.1080/07391102.2012.689699

Related Stories

Recommended for you

A cheaper, high-performance prosthetic knee

July 30, 2015

In the last two decades, prosthetic limb technology has grown by leaps and bounds. Today, the most advanced prostheses incorporate microprocessors that work with onboard gyroscopes, accelerometers, and hydraulics to enable ...

Crystal clear images uncover secrets of hormone receptors

July 31, 2015

Many hormones and neurotransmitters work by binding to receptors on a cell's exterior surface. This activates receptors causing them to twist, turn and spark chemical reactions inside cells. NIH scientists used atomic level ...

Flow means 'go' for proper lymph system development

July 27, 2015

The lymphatic system provides a slow flow of fluid from our organs and tissues into the bloodstream. It returns fluid and proteins that leak from blood vessels, provides passage for immune and inflammatory cells from the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.